Discover open access scientific publications

Search, annotate, share and cite publications

Publications by G. Bootsma

OA07.07 PFS and OS Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)

Journal of Thoracic Oncology

English

Related publications

MA05.09 PFS and Cardiac-Toxicity-Adjusted-PFS as Predictors of OS in Locally Advanced NSCLC Treated With Concurrent Chemoradiation

Journal of Thoracic Oncology

English

Population-Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for Up to 5 Oligometastases: SABR-5

English

Pemetrexed for Previously Treated Patients With Metastatic Gastric Cancer: A Prospective Phase II Study

British Journal of Cancer

Cancer Research

Oncology

2014

English

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated With Chemotherapy

Journal of Thoracic Oncology

English

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated After Chemoradiotherapy and an 8-Year Update on a Phase I/Ii Trial

Clinical Cancer Research

Cancer Research

Oncology

2011

English

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab in Patients With Unresectable Stage III NSCLC

Journal of Thoracic Oncology

English

A Phase II Trial of Ixabepilone in Asian Patients With Advanced Gastric Cancer Previously Treated With Fluoropyrimidine-Based Chemotherapy

Cancer Chemotherapy and Pharmacology

English

MINI01.02: Response and Plasma Genotyping From Phase I/Ii Trial of Ensartinib (X-396) in Patients (Pts) With ALK+ NSCLC

Journal of Thoracic Oncology

English

Mitomycin C and Vinorelbine for Second-Line Chemotherapy in NSCLC – A Phase II Trial

British Journal of Cancer

Cancer Research

Oncology

2007

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by G. Bootsma

OA07.07 PFS and OS Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)

Related publications

MA05.09 PFS and Cardiac-Toxicity-Adjusted-PFS as Predictors of OS in Locally Advanced NSCLC Treated With Concurrent Chemoradiation

Population-Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for Up to 5 Oligometastases: SABR-5

Pemetrexed for Previously Treated Patients With Metastatic Gastric Cancer: A Prospective Phase II Study

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated With Chemotherapy

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated After Chemoradiotherapy and an 8-Year Update on a Phase I/Ii Trial

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab in Patients With Unresectable Stage III NSCLC

A Phase II Trial of Ixabepilone in Asian Patients With Advanced Gastric Cancer Previously Treated With Fluoropyrimidine-Based Chemotherapy

MINI01.02: Response and Plasma Genotyping From Phase I/Ii Trial of Ensartinib (X-396) in Patients (Pts) With ALK+ NSCLC

Mitomycin C and Vinorelbine for Second-Line Chemotherapy in NSCLC – A Phase II Trial